Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis

(2020) Sabrina Paganoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

(2020) Jeremy M. Shefner et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

NIV in amyotrophic lateral sclerosis: The ‘when’ and ‘how’ of the matter

(2019) Capucine Morelot‐Panzini et al.   RESPIROLOGY

Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial

(2019) Ammar Al-Chalabi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Potential of the Cardiovascular Drug Levosimendan in the Management of Amyotrophic Lateral Sclerosis

(2019) Ammar Al-Chalabi et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study

(2018) Ton Fang et al.   LANCET NEUROLOGY

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

(2017) Koji Abe et al.   LANCET NEUROLOGY

Amyotrophic Lateral Sclerosis

(2017) Robert H. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis

(2016) Jeremy M. Shefner et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials

(2013) James D. Berry et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations

(2012) Philip H. Quanjer et al.   EUROPEAN RESPIRATORY JOURNAL

The Calcium Sensitizer Levosimendan Improves Human Diaphragm Function

(2011) Jonne Doorduin et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force

(2011) et al.   EUROPEAN JOURNAL OF NEUROLOGY

The Borg dyspnoea score: a relevant clinical marker of inspiratory muscle weakness in amyotrophic lateral sclerosis

(2009) N. Just et al.   EUROPEAN RESPIRATORY JOURNAL

Levosimendan Enhances Force Generation of Diaphragm Muscle from Patients with Chronic Obstructive Pulmonary Disease

(2008) Hieronymus W. H. van Hees et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE